Latent tuberculosis screening for inflammatory bowel disease in tuberculosis endemic region remains porous and suboptimal: A multicentre study

doi:10.3748/wjg.v32.i4.114897

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 4

This Article

(44)

(96)

(0)

(20)

(1506)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Jan 28, 2026; 32(4): 114897
Published online Jan 28, 2026. doi: 10.3748/wjg.v32.i4.114897

Table 3 Characteristics of latent and active tuberculosis, n (%)

Variables
No of patients with LTB¹	40/373 (10.72)
CD	23/216 (10.6)
UC	16/158 (10.1)
IBD-U	1/4 (25)
Basis of LTB²
IGRA	21/40 (52.50)
TST	9/40 (22.50)
CT chest	11/40 (27.50)
Past history of incomplete TB treatment	2/40 (5)
History of contact with pulmonary TB	1/40 (2.5)
LTB positive patients receiving treatment³	25/40 (62.50)
No of patients with active TB	17/378 (4.49)
Pulmonary	9 (52.94)
Extrapulmonary	8 (47.05)
Advanced therapy used among active TB
Anti-TNFi	15 (88.2)
Infliximab	12
Adalimumab	3
Tofacitinib	1 (5.88)
Vedolizumab	1 (5.88)
Median time to develop TB after advanced therapy initiation	7 (4-8) months

¹Five patients no screening done.

²Combination of test positive (n = 6).

³Total 28 received prophylactic treatment for latent tuberculosis, 3 patients received prophylactic therapy exclusively based on past history of tuberculosis.

LTB: Latent tuberculosis; CD: Crohn’s disease; UC: Ulcerative colitis; IBD: Inflammatory bowel disease; IGRA: Interferon-gamma release assay; TST: Tuberculin skin test; CT: Computed tomography; TB: Tuberculosis; TNFi: Tumor necrosis factor inhibitor.

Full Size Table

Citation: Jha DK, Prasad S, Valsan A, Mishra S, Nair P, Koshy AK, Singh S, Prasad AS, Shukla R, Ahamed R, Augustine P, Natarajan K, Peddi K, Kulkarni A, Bhatia S, Pachisia AV, Singh PK, Jena A, Gupta S, Jain S, Padmaprakash K, Kakadiya R, Kumar A, Shukla S, Dutta U, Hande V, Thareja S, Sharma V. Latent tuberculosis screening for inflammatory bowel disease in tuberculosis endemic region remains porous and suboptimal: A multicentre study. World J Gastroenterol 2026; 32(4): 114897
URL: https://www.wjgnet.com/1007-9327/full/v32/i4/114897.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i4.114897

Jha DK, Prasad S, Valsan A, Mishra S, Nair P, Koshy AK, Singh S, Prasad AS, Shukla R, Ahamed R, Augustine P, Natarajan K, Peddi K, Kulkarni A, Bhatia S, Pachisia AV, Singh PK, Jena A, Gupta S, Jain S, Padmaprakash K, Kakadiya R, Kumar A, Shukla S, Dutta U, Hande V, Thareja S, Sharma V. Latent tuberculosis screening for inflammatory bowel disease in tuberculosis endemic region remains porous and suboptimal: A multicentre study. World J Gastroenterol 2026; 32(4): 114897 [PMID: 41640875 DOI: 10.3748/wjg.v32.i4.114897]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.